Advertisement


Rana R. McKay, MD, on RCC: Continuing Benefit After Halting Treatment

2017 Genitourinary Cancers Symposium

Advertisement

Rana R. McKay, MD, of the University of California, San Diego, discusses study findings on PD-1/PD-L1 responders with metastatic renal cell carcinoma who discontinue therapy for immune-related adverse events. (Abstract 467)



Related Videos

Solid Tumors

George J. Bosl, MD, and Karim Fizazi, MD, PhD, on Germ Cell Tumors and Treatment Intensification: Pros and Cons

George J. Bosl, MD, of Memorial Sloan Kettering Cancer Center, and Karim Fizazi, MD, PhD, of Gustave Roussy and the University of Paris Sud, offer the “pro” and “con” viewpoints for treatment intensification in patients with poor-prognosis germ cell tumors with unfavorable marker decline.

Issues in Oncology

Brian C. Allen, MD, on Assessing Tumor Response: Standard-of-Care vs Computer-Assisted Evaluation

Brian C. Allen, MD, of Duke University Medical Center, discusses the benefits of using a computerized process that provides step-wise guidance, decreases interpretation time, and reduces errors when measuring tumor response to treatment. (Abstract 432)

Prostate Cancer

Charles G. Drake, MD, PhD, on Prostate Cancer and Immunology: Expert Perspective

Charles G. Drake, MD, PhD, of Columbia University Medical Center, summarizes his keynote lecture on immunotherapy as a new frontier in prostate cancer and its synergistic use with traditional treatments.

Bladder Cancer

Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response (German Language Version)

Roland Seiler, MD, of the University of British Columbia, discusses in German a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplatin-based neoadjuvant chemotherapy, and which patients show the most benefit. (Abstract 281)

Bladder Cancer

Emma Hall, PhD, on Bladder Cancer: Results From the BC2001 Trial

Emma Hall, PhD, of the Institute of Cancer Research, London, discusses long-term outcomes with chemoradiotherapy vs radiotherapy alone, and standard vs reduced high-dose volume radiotherapy in muscle-invasive bladder cancer. (Abstract 280)

Advertisement

Advertisement




Advertisement